Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2022-05-31 AGM Information
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Kommuniké från Karo Pharmas årsstämma 2022
AGM Information Classification · 98% confidence The document title is "Kommuniké från Karo Pharmas årsstämma 2022" (Communiqué from Karo Pharma's Annual General Meeting 2022). The text details decisions made during the AGM regarding the approval of financial statements, election of the board, remuneration, auditor appointment, and changes to the articles of association and authorization for new share issues. These topics are central to an Annual General Meeting. Since the document is a summary/communiqué of the meeting's outcomes rather than the full presentation materials or the formal voting results declaration, the most appropriate classification is AGM Information (AGM-R). It is not a DEF 14A (Remuneration) because it covers many other AGM topics, nor is it DVA (Declaration of Voting Results) as it reports the decisions made, not the detailed vote counts.
2022-05-31 Swedish
Ändringar i Karo Intressenter AB:s förslag avseende val av styrelse till Karo Pharmas årsstämma 2022
Board/Management Information Classification · 95% confidence The document is titled 'Karo Pharma AR' (which often stands for Annual Report, but the content suggests otherwise) and discusses changes to the proposal for the Board of Directors ('val av styrelse') for the Annual General Meeting (AGM) scheduled for May 31, 2022. Specifically, it details a change in the proposed number of directors and the nomination of a new director, Claire Hennah, along with her proposed remuneration. This content directly relates to the composition of the board and proposals being voted on at the AGM. This falls under Board/Management Information (MANG) or potentially AGM-related material. Since the core subject is the proposal for board composition changes announced shortly before the AGM, MANG is a strong fit, as it covers changes in senior management/board. However, given the context of the AGM and the specific nature of board member proposals, AGM-R (AGM Information) is also highly relevant. Since the document is an announcement detailing a change in the proposed board composition for the upcoming AGM, it is most accurately classified as Board/Management Information (MANG) regarding director appointments, or potentially AGM-R if it were the final slate. Given the focus on the *change* in the board proposal, MANG is slightly more precise than the general AGM material (AGM-R). However, looking closely at the definitions, MANG is for 'Announcement of changes in the company's board of directors or senior management.' This document is exactly that: an announcement of a change in the proposed board composition. The document length is short (2897 chars) and it is an announcement, not the full AGM presentation.
2022-05-27 Swedish
KALLELSE TILL ÅRSSTÄMMA I KARO PHARMA AKTIEBOLAG
AGM Information Classification · 100% confidence The document is titled 'KALLELSE TILL ÅRSSTÄMMA I KARO PHARMA AKTIEBOLAG', which translates to 'NOTICE OF ANNUAL GENERAL MEETING IN KARO PHARMA AB'. It details the procedures for shareholders to participate via postal voting, the agenda items typical for an AGM (election of chairman, approval of the board, dividend proposal, changes to articles of association), and specific dates related to the meeting (May 31, 2022). This content directly corresponds to the notice and materials distributed for an Annual General Meeting. Therefore, the classification is AGM-R.
2022-05-02 Swedish
Karo Pharmas företrädesemission fulltecknad
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Karo Pharma AB announcing that its rights issue ("Företrädesemissionen") was fully subscribed, detailing the amount raised (approx. 2.5 billion SEK), the number of shares subscribed, and the expected registration and trading dates for the new shares. This announcement concerns a significant capital raising and share structure change. This fits the definition of 'Capital/Financing Update' (CAP) as it details the outcome of a fundraising activity. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital structure changes resulting from financing.
2022-04-19 Swedish
Karo Pharma’s rights issue fully subscribed
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Karo Pharma Aktiebolag's rights issue of approximately SEK 2.5 billion is fully subscribed. It details the subscription results, allotment procedures, expected registration/trading dates, and the resulting increase in share capital and number of shares. This content directly relates to a corporate financing activity, specifically the completion of a capital raise via a rights issue. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific, major financing event.
2022-04-19 English
Karo Pharma slutför förvärvet av E45® från Reckitt
M&A Activity Classification · 99% confidence The document announces the completion of an acquisition (Karo Pharma finalizing the purchase of the E45® brand from Reckitt for 200 million GBP). It includes financial context (2021 revenue of E45®) and quotes from the CEO. Crucially, the final paragraph states: "Denna information är sådan som Karo Pharma Aktiebolag (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such that Karo Pharma AB (publ) is obliged to make public pursuant to the EU's Market Abuse Regulation). This strongly indicates a mandatory regulatory disclosure regarding a significant corporate event (M&A activity). While it relates to M&A (TAR), the nature of the announcement—a mandatory disclosure under MAR—often defaults to a general regulatory filing if a more specific code for M&A completion isn't available, or if it's a broad announcement. Given the options, 'M&A Activity' (TAR) is the most specific fit for an acquisition completion announcement. However, since this is a press release format announcing a transaction completion, and not a formal tender offer document, 'Regulatory Filings' (RNS) is often used for general MAR disclosures that aren't standard periodic reports (10-K, IR, etc.). Since TAR specifically covers 'merger proposals or takeover bids' and this is the completion of an acquisition, TAR is the best fit for the subject matter, even if it's presented as a press release.
2022-04-01 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.